Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 4/20 | 0.46 |
| ▸ | THRB | P10828 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945985 | 0.92 | ALDH1A1 (0.40) | THRATHRBKDM4EALDH1A1KMT2A | |
| SCHEMBL3315111 | 0.91 | THRA (0.48) | THRATHRBKDM4EALDH1A1KMT2A | |
| SCHEMBL3319730 | 0.83 | ALDH1A1 (0.41) | THRATHRBKDM4EALDH1A1KMT2A | |
| SCHEMBL12833107 | 0.82 | THRA (0.57) | THRATHRBKDM4EALDH1A1KMT2A | |
| SCHEMBL12440958 | 0.77 | MAPT (0.59) | THRATHRBKDM4EALDH1A1KMT2A | |
| SCHEMBL9945984 | 0.77 | THRA (0.40) | THRATHRBKDM4EALDH1A1KMT2A | |
| SCHEMBL9946066 | 0.77 | THRA (0.51) | THRATHRBKDM4EALDH1A1KMT2A | |
| SCHEMBL9945938 | 0.76 | ALDH1A1 (0.39) | THRATHRBALDH1A1KMT2AMEN1 | |
| SCHEMBL3318902 | 0.76 | THRB (0.44) | THRBKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL13429866 | 0.74 | THRA (0.46) | THRATHRBKDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | THRA 1584/4885THRB 898/4885KDM4E 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.